Zhitong Finance App News, Kangzhe Pharmaceutical (00867.HK) announced that on September 11, 2026, the innovative drug CMS-D001 tablets obtained a drug clinical trial approval notice issued by China's National Drug Administration (NMPA), and received a drug clinical trial approval notice on September 14, 2026. NMPA agreed with the Group to conduct clinical trials to evaluate the efficacy and safety of CMS-D001 in the treatment of systemic lupus erythematosus.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.